SEC Form 4 · accession 0001140361-18-012906
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Harris
Officer — Head of Corporate Development · Director
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 7, 2018 | S | 3,704 | $20.00 | D | 628,362 | D | |
| Common StockF2 | Mar 8, 2018 | S | 14,530 | $20.0342 | D | 613,832 | D | |
| Common StockF3 | Mar 9, 2018 | S | 2,438 | $20.0099 | D | 611,394 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017.
- F2This transaction was executed in multiple trades in prices ranging from $20.00 to $20.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3This transaction was executed in multiple trades in prices ranging from $20.00 to $20.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.